Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from New England Journal of Medicine

‘Night and day’: Parkinson’s symptoms eased by non-surgical procedure, study shows

BALTIMORE -- The other day, Melanie Carlson took her 5-year-old daughter shopping for a bathing suit.

Tribune News Service

Doctors find enormous parasite the size of a FIST inside brain of 14-year-old boy

WARNING GRAPHIC CONTENT: The unnamed 14-year-old had been experiencing headaches and vomiting for a month before the gruesome discovery in India and reported in The New England Journal of Medicine (NEJM)

Daily Mirror

A Promising Covid-19 Antiviral Cuts Hospitalizations in Half — Will Americans Get It?

We may have a new, versatile antiviral to add to the arsenal, according to a study published this week in the New England Journal of Medicine.

Inverse

From analysis to the latest developments in health,
read the most diverse news in one place.

Meet the Scientists Who Want to Make Medical Devices Work for Everyone, Finally

Can scientists fix the racial biases baked into medicine, starting with the ubiquitous pulse oximeter?

Inverse

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune

Did Damar Hamlin experience commotio cordis? What to know about the rare phenomenon

It involves the impact of a specific force to the chest at a specific moment in the cardiac cycle. One cardiologist told NPR that what happened to Hamlin was likely "a perfect storm of events."

WEKU

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Health: New Treatment Discovered For Rare Eye Disease May Prevent Blindness

Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine. Read on for details:

Dynamite News

A new drug appears to slow Alzheimer’s. Here’s what to know

An experimental drug appears to slow cognitive decline in people with early onset Alzheimer’s.

Tribune News Service

For some COVID patients, 'Paxlovid rebound' has nothing to do with Paxlovid

This is a story about a COVID-19 medication, a nasty trick the coronavirus sometimes plays on its victims, and how the two became a pandemic couple called "Paxlovid rebound."

Los Angeles Times

Faye Flam: Better cancer screenings are coming. Can we afford them?

Patients and their doctors count on cancer screening tests to save lives, and yet a number of large, controlled studies are showing disappointing results for mammography and other mass screening tests. This month, the New England Journal of Medicine published a controversial study that cast doubt on the widely accepted…

Tribune News Service

Colonoscopies save lives. Doctors push back against European study that casts doubt

Colon cancer specialists worry that results of a study published this week in the New England Journal of Medicine could be misconstrued, and keep patients from getting lifesaving cancer screening.

WEKU

Patients hail new treatment for drug-resistant TB

PARIS: Volodymyr celebrated a major milestone on Wednesday - his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.

Bangkok Post

'Beginning of the end': patients hail new treatment for drug-resistant TB

Paris (AFP) - Volodymyr is celebrating a major milestone on Wednesday -- it's his final day of taking a new treatment hailed as a turning point in the fight against drug-resistant tuberculosis.

AFP

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Coronary artery stents show no benefit in treating heart failure – landmark trial

Every year, 60,000 people in the UK are diagnosed with heart failure, and many are treated with stents. In a large new study published in the New England Journal of Medicine, my colleagues and I discovered that these procedures are unnecessary.

ABC News

Vaccines are now approved for children aged six months to five years, but what about newborn babies?

COVID-19 vaccines are now approved for children aged from six months up to five years and are already being rolled out to about 70,000 at-risk youngsters.

Benzinga

ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Daily Mirror

New monkeypox study warns virus has 'no borders’ as more symptoms detailed

New symptoms have been found of the monkeypox virus in a new study, the largest so far, by the New England Journal of Medicine, with a lead author saying the virus "has no borders"

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

When it comes to darker skin, pulse oximeters fall short

These devices measure blood oxygen levels and can help identify when patients are dangerously ill. But research shows they can deliver misleading results for people with darker skin.

Inverse

Climate change and air pollution are wrecking children’s health, a landmark review reveals

New research highlights the public health threat of climate change and air pollution to children and offers recommendations to healthcare professionals.

The Independent UK

Guns kill more teens and kids in America than drugs or cancer, report finds

Benzinga

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. There were no…

Benzinga

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Results from the Phase 1/2 dose-finding study evaluating Sanofi SA's (NASDAQ:SNY) rilzabrutinib in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate that rilzabrutinib treatment led to a rapid and durable increase in platelet count and supports an acceptable safety profile. Sanofi is investigating…

Chicago Sun-Times

For weekend warriors, most Achilles tendon ruptures heal as well without surgery, study finds

Research published by the New England Journal of Medicine found only slight differences in recovery after a year whether patients had surgery or nonsurgical treatment.

Chicago Tribune

Commentary: Is a second booster for COVID-19 the right choice for you?

The Food and Drug Administration and the Centers for Disease Control and Prevention recently authorized a second booster shot of the Pfizer/BioNTech and Moderna COVID-19 vaccines for those age 50 and older. The recommendation follows a study out of Israel recently published in The New England Journal of Medicine.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

333 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.